Aine Hanly, Ph.D.

Executive Vice President and Chief Technology Officer

Aine Hanly, Ph.D., has served as Vir’s Executive Vice President and Chief Technology Officer since March 2021. She oversees the Company’s technical operations, including product and process development, supply chain, manufacturing, quality and CMC strategy. Her career in the biomanufacturing industry, which has spanned roles in the United Kingdom, Ireland and the United States, has been dedicated to advancing innovative solutions to accelerate the delivery of medicines to patients.

Prior to joining Vir, Dr. Hanly served as the Vice President of Process Development for Amgen, accountable for clinical manufacturing and global supply of clinical trial materials. During her nearly decade-long tenure, she led teams that enabled the commercialization of Amgen’s pipeline products and provided technical support for ongoing commercial manufacturing operations. Prior to that, she worked for more than 10 years at Pfizer (formerly, Wyeth), where she held roles of increasing responsibility in analytical R&D, process development, quality and product supply strategy.

Dr. Hanly received a B.S. in biological chemistry and a Ph.D. in physical organic chemistry from the University of Ulster, Northern Ireland. She completed her post-doctoral fellowship at Creighton University School of Medicine before joining the collaborative research wing at Yale University and CuraGen Corporation as lead scientist studying gene isolation and subsequent confirmation using a variety of molecular biology techniques.